Dendrogenix CEO, CSO and CDO will attend to BioEquity Europe 2025 | May 12–14, 2025 | Bruges, Belgium. Celebrating its 25th year, BioEquity Europe is the destination event for biopharma decision-makers to network, partner and debate critical issues facing the biotech industry.
During the SFN 2024 edition in Chicago, Dr. Quentin Marlier, head of biology at Dendrogenix, will present a poster publication called “Improvement of neurological outcomes following Stroke or traumatic brain injury in mice treated with a novel first-in-class compound” to expose preclinical data regarding its lead compound DX243 in stroke and TBI model.
DENDROGENIX S.A.
Founded in 2018, Dendrogenix develop first-in-class molecules, Dendrogenins, to address high unmet medical needs in hearing loss and neurology.
© 2024 Dendrogenix
Latest News
Contact
Avenue de l’Hôpital, 11
SPS Bâtiment 34, 3e étage
4000 Liège
Belgium